Genentech announces FDA approval of Xofluza (baloxavir marboxil) for influenza
SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action
